NHOS is the only currently available treatment target in HF and should be combatted in most patients with the combined use of diuretics and neurohormonal inhibitors (β-blockers/angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid antagonists, and SGLT-2i) [5,36,37,38,39]. This evidence concerns the gene ACE and hydrops fetalis.